Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.


  Lung Cancer

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    June 2025
  1. WANG K, Xiang J, Zhou J, Chen C, et al
    Development and validation of a transcription factor regulatory network-based signature for individualized prognostic risk in lung adenocarcinoma.
    Int J Cancer. 2025;156:2440-2451.
    PubMed     Abstract available


    April 2025
  2. XIE Y, Fang H, Cheng W, Xu T, et al
    Furmonertinib in uncommon EGFR-mutated non-small cell lung cancer with central nervous system metastases: A retrospective cohort study.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35460.
    PubMed     Abstract available


  3. TSURUDA KM, Hektoen HH, Aamelfot C, Andreassen BK, et al
    Let's talk about sex: Survival among females and males in a real-world cohort treated with pembrolizumab for non-small cell lung cancer.
    Int J Cancer. 2025 Apr 29. doi: 10.1002/ijc.35445.
    PubMed     Abstract available


  4. NOFAL S, J Ostrin E, Zhang J, Wu J, et al
    Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35452.
    PubMed     Abstract available


  5. DIAO M, Wang Y, Wu S, He S, et al
    Estrogen, estrogen receptor and the tumor microenvironment of NSCLC.
    Int J Cancer. 2025;156:1501-1508.
    PubMed     Abstract available


  6. NOMURA K, Takada K, Kinoshita F, Muto S, et al
    Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).
    Int J Cancer. 2025;156:1480-1491.
    PubMed     Abstract available


    March 2025
  7. HEMMINKI K, Zitricky F, Sundquist K, Sundquist J, et al
    Sex specific familial risk in lung cancer through changing histologies in Sweden.
    Int J Cancer. 2025 Mar 29. doi: 10.1002/ijc.35431.
    PubMed     Abstract available


    February 2025
  8. XU H, Fu X, Wang S, Ge Y, et al
    Immunoglobulin-like transcript 5 polarizes M2-like tumor-associated macrophages for immunosuppression in non-small cell lung cancer.
    Int J Cancer. 2025 Feb 5. doi: 10.1002/ijc.35360.
    PubMed     Abstract available


    January 2025
  9. NALWOGA A, Jackson C, Fiorillo S, Manyeruke F, et al
    Evaluation of plasma alpha-1-antichymotrypsin as a marker for pulmonary Kaposi sarcoma.
    Int J Cancer. 2025 Jan 30. doi: 10.1002/ijc.35351.
    PubMed     Abstract available


  10. KANZAKI R, Reid S, Bolivar P, Sjolund J, et al
    FHL2 expression by cancer-associated fibroblasts promotes metastasis and angiogenesis in lung adenocarcinoma.
    Int J Cancer. 2025;156:431-446.
    PubMed     Abstract available


  11. LAZZARI N, Rigotto G, Montini B, Del Bianco P, et al
    Stemness and hybrid epithelial-mesenchymal profiles guide peritoneal dissemination of malignant mesothelioma and pseudomyxoma peritonei.
    Int J Cancer. 2025;156:201-215.
    PubMed     Abstract available


    December 2024
  12. CHEI CL, Nakamura S, Watanabe K, Mizutani T, et al
    Assessing the performance of chest x-ray screening in detecting early-stage lung cancer in the general population.
    Int J Cancer. 2024 Dec 30. doi: 10.1002/ijc.35316.
    PubMed     Abstract available


  13. LU G, Liu H, Wang H, Luo S, et al
    Genetic variants of FER and SULF1 in the fibroblast-related genes are associated with non-small-cell lung cancer survival.
    Int J Cancer. 2024 Dec 20. doi: 10.1002/ijc.35305.
    PubMed     Abstract available


  14. YANG ZM, Qin XY, Lu YY, Yao LK, et al
    Pathogen spectrum and clinical characteristics of lung cancer patients: A 10-year retrospective study.
    Int J Cancer. 2024 Dec 16. doi: 10.1002/ijc.35272.
    PubMed     Abstract available


  15. BRANCO H, Rodrigues CA, Oliveira J, Mendes N, et al
    Preclinical studies on the antitumor and non-toxic effect of combining pirfenidone with vinorelbine and carboplatin in non-small cell lung cancer.
    Int J Cancer. 2024 Dec 4. doi: 10.1002/ijc.35276.
    PubMed     Abstract available


    November 2024
  16. BURUS T, Patel MI, Christian WJ, Huang B, et al
    Sex-based differences in histologic lung cancer incidence trends in the United States, 2005-2019.
    Int J Cancer. 2024 Nov 21. doi: 10.1002/ijc.35268.
    PubMed     Abstract available


  17. JIANG C, Freedman RA, Punglia RS, Jemal A, et al
    Associations of radiotherapy receipt with lung cancer risk by histological subtype among breast cancer survivors in the United States.
    Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35257.
    PubMed     Abstract available


  18. TAKADA K, Takamori S, Shimokawa M, Pinato DJ, et al
    Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial.
    Int J Cancer. 2024 Nov 5. doi: 10.1002/ijc.35249.
    PubMed     Abstract available


    October 2024
  19. JEMAL A, Schafer EJ, Star J, Bandi P, et al
    Lung cancer incidence rates in young women and men by state in the United States.
    Int J Cancer. 2024 Oct 11. doi: 10.1002/ijc.35188.
    PubMed     Abstract available


  20. MA Z, Zhu Z, Pang G, Gong F, et al
    Development and validation of a lung cancer polygenic risk score incorporating susceptibility variants for risk factors.
    Int J Cancer. 2024 Oct 8. doi: 10.1002/ijc.35210.
    PubMed     Abstract available


  21. KISHIDA R, Yin X, Abe SK, Rahman MS, et al
    Association between family history with lung cancer incidence and mortality risk in the Asia Cohort Consortium.
    Int J Cancer. 2024 Oct 3. doi: 10.1002/ijc.35191.
    PubMed     Abstract available


    September 2024
  22. HU H, Zhu Q, Tang H, Zhang SC, et al
    The risk of treatment-related toxicities with PD-1/PD-L1 inhibitors in patients with lung cancer.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35195.
    PubMed     Abstract available


  23. WANG H, Liu H, Tang X, Lu G, et al
    Potentially functional variants of PARK7 and DDR2 in ferroptosis-related genes predict survival of non-small cell lung cancer patients.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35197.
    PubMed     Abstract available


  24. WIESWEG M, Kuter C, Schnorbach J, Keyl J, et al
    Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome.
    Int J Cancer. 2024 Sep 25. doi: 10.1002/ijc.35199.
    PubMed     Abstract available


    August 2024
  25. SCHULTE C, Gauler T, Pottgen C, Friedel G, et al
    Survivorship program including long-term toxicities and quality-of-life development over 10 years in a randomized trial in operable stage III non-small-cell lung cancer (ESPATUE).
    Int J Cancer. 2024 Aug 28. doi: 10.1002/ijc.35131.
    PubMed     Abstract available


  26. CHEN S, Cheng S, Cai J, Liu Z, et al
    The current therapeutic cancer vaccines landscape in non-small cell lung cancer.
    Int J Cancer. 2024 Aug 7. doi: 10.1002/ijc.35088.
    PubMed     Abstract available


    July 2024
  27. PULAWSKA-MOON K, Ponikwicka-Tyszko D, Lebiedzinska W, Pilaszewicz-Puza A, et al
    Novel ectopic expression of zona pellucida 3 glycoprotein in lung cancer promotes tumor growth.
    Int J Cancer. 2024 Jul 22. doi: 10.1002/ijc.35098.
    PubMed     Abstract available


  28. BRATIVNYK A, Ankill J, Helland A, Fleischer T, et al
    Multi-omics analysis reveals epigenetically regulated processes and patient classification in lung adenocarcinoma.
    Int J Cancer. 2024;155:282-297.
    PubMed     Abstract available


  29. YIN M, Liu L, Yan Y, Wang H, et al
    A targeting nanoplatform for chemo-photothermal synergistic therapy of small-cell lung cancer.
    Int J Cancer. 2024 Jul 10. doi: 10.1002/ijc.35065.
    PubMed     Abstract available


  30. ZHANG Q, Chen K, Yu X, Fan Y, et al
    Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.
    Int J Cancer. 2024 Jul 3. doi: 10.1002/ijc.35070.
    PubMed     Abstract available


    June 2024
  31. MELOSKY B, Vincent MD, McGuire AL, Brade AM, et al
    Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.
    Int J Cancer. 2024 Jun 20. doi: 10.1002/ijc.35031.
    PubMed     Abstract available


  32. ZHANG B, Li C, Wu J, Zhang J, et al
    DeepCG: A cell graph model for predicting prognosis in lung adenocarcinoma.
    Int J Cancer. 2024;154:2151-2161.
    PubMed     Abstract available


  33. CHEN C, Zhou X, Gao X, Pan R, et al
    Immune responses and reinfection of SARS-CoV-2 Omicron variant in patients with lung cancer.
    Int J Cancer. 2024 Jun 5. doi: 10.1002/ijc.35038.
    PubMed     Abstract available


  34. GU Z, Huang P, Zhao J, Luo C, et al
    Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
    Int J Cancer. 2024;154:1979-1986.
    PubMed     Abstract available


  35. SEBASTIAN M, Eberhardt WEE, von der Heyde E, Dorfel S, et al
    Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315).
    Int J Cancer. 2024;154:1967-1978.
    PubMed     Abstract available


    May 2024
  36. MIYAMORI D, Kamitani T, Yoshida S, Kikuchi Y, et al
    Effects of the Coronavirus disease 2019 pandemic on mortality in patients with lung cancer: A multiple mediation analysis in Japan.
    Int J Cancer. 2024 May 24. doi: 10.1002/ijc.35042.
    PubMed     Abstract available


  37. WANG Z, Zhang Q, Wang C, Herth FJF, et al
    Multiple primary lung cancer: Updates and perspectives.
    Int J Cancer. 2024 May 23. doi: 10.1002/ijc.34994.
    PubMed     Abstract available


  38. KOURO T, Higashijima N, Horaguchi S, Mano Y, et al
    Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.
    Int J Cancer. 2024;154:1828-1841.
    PubMed     Abstract available


    April 2024
  39. RAHMAN ML, Shu XO, Jones DP, Hu W, et al
    A nested case-control study of untargeted plasma metabolomics and lung cancer among never-smoking women within the prospective Shanghai Women's Health Study.
    Int J Cancer. 2024 Apr 23. doi: 10.1002/ijc.34929.
    PubMed     Abstract available


  40. MULSHINE JL, Avila RS, Rizzo AA, Estepar RSJ, et al
    Quantitative imaging workshop XIX: Utilizing quantitative thoracic imaging to optimize population health final summary.
    Int J Cancer. 2024;154:1365-1370.
    PubMed     Abstract available


    March 2024
  41. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available


    February 2024
  42. YIN X, Kishida R, Abe SK, Islam MR, et al
    Association between reproductive factors with lung cancer incidence and mortality: A pooled analysis of over 308,000 females in the Asia cohort consortium.
    Int J Cancer. 2024 Feb 20. doi: 10.1002/ijc.34866.
    PubMed     Abstract available


  43. WELSCH E, Holzer B, Schuster E, Fabikan H, et al
    Prognostic significance of circulating tumor cells and tumor related transcripts in small cell lung cancer: A step further to clinical implementation.
    Int J Cancer. 2024 Feb 14. doi: 10.1002/ijc.34886.
    PubMed     Abstract available


    January 2024
  44. MORITA A, Ichihara E, Inoue K, Fujiwara K, et al
    Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Int J Cancer. 2024 Jan 9. doi: 10.1002/ijc.34842.
    PubMed     Abstract available


  45. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available


  46. KEMMOTSU N, Ninomiya K, Kunimasa K, Ishino T, et al
    Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
    Int J Cancer. 2024;154:169-179.
    PubMed     Abstract available


    December 2023
  47. MORISUE R, Kojima M, Suzuki T, Watanabe R, et al
    Common clinicopathological and immunological features of sarcomatoid carcinoma across organs: A histomorphology-based cross-organ study.
    Int J Cancer. 2023;153:1997-2010.
    PubMed     Abstract available


    November 2023
  48. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    PubMed     Abstract available


  49. PELOS G, Riester M, Pal J, Myacheva K, et al
    Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment.
    Int J Cancer. 2023 Nov 10. doi: 10.1002/ijc.34783.
    PubMed     Abstract available


    October 2023
  50. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    PubMed     Abstract available


  51. WEI X, Sun D, Gao J, Zhang J, et al
    Development and evaluation of a polygenic risk score for lung cancer in never-smoking women: A large-scale prospective Chinese cohort study.
    Int J Cancer. 2023 Oct 17. doi: 10.1002/ijc.34765.
    PubMed     Abstract available


  52. VAN VEELEN A, Veerman GDM, Verschueren MV, Gulikers JL, et al
    Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.
    Int J Cancer. 2023 Oct 15. doi: 10.1002/ijc.34742.
    PubMed     Abstract available


  53. YU Z, Ni P, Yu H, Zuo T, et al
    Effectiveness of a single low-dose computed tomography screening for lung cancer: A population-based perspective cohort study in China.
    Int J Cancer. 2023 Oct 11. doi: 10.1002/ijc.34741.
    PubMed     Abstract available


  54. TOMONAGA Y, de Nijs K, Bucher HC, de Koning H, et al
    Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.
    Int J Cancer. 2023 Oct 4. doi: 10.1002/ijc.34746.
    PubMed     Abstract available


    September 2023
  55. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.